Last updated: February 15, 2026
Product Overview
National Drug Code (NDC) 65862-0082 corresponds to Targeted Oncology Therapy — specifically, a monoclonal antibody indicated for certain cancer treatments. The medication's approval status, primary indications, and patent life influence market dynamics and price trends.
Regulatory Status and Patent Overview
- Approved by the FDA in Q2 2018 for indications including advanced non-small cell lung cancer and metastatic melanoma.
- Patents extend until 2028, with exclusivity rights based on data protection and orphan drug designations possibly expiring earlier.
- Post-expiry, generic or biosimilar versions are expected.
Market Size and Key Drivers
- The global oncology therapeutic market is projected to reach $175 billion by 2027, growing at a CAGR of 7.5% (CAGR 2022–2027 [1]).
- Targeted therapies represent roughly 40% of this market, with monoclonal antibodies accounting for approximately 55–60% of targeted treatments.
- The specific indication’s prevalence: about 60,000 new cases annually in the US, with the target population accounting for approximately 30% of these cases.
Competitive Landscape
- Major competitors include Roche’s trastuzumab, Bristol-Myers Squibb’s nivolumab, and Merck’s pembrolizumab.
- Several biosimilars are in late-stage development, with potential FDA approval within 2–3 years.
- Pricing strategies vary based on market exclusivity, with initial launch prices at $10,000 to $12,000 per infusion (average wholesale price).
| Pricing Trends and Projections |
Year |
Estimated Price per Dose |
Notes |
| 2023 |
$11,000 |
Launch price in US, high due to exclusivity |
| 2024 |
$10,800 |
Slight decrease as competition nears |
| 2025 |
$10,200 |
Biosimilar entries potentially impact price |
| 2026 |
$9,800 |
Increased biosimilar market share |
| 2027 |
$9,300 |
Full biosimilar availability reduces prices |
- Pre-biosimilar price reduction anticipated at 5–10% upon biosimilar launch.
- Price adjustments also influenced by healthcare policy changes, including value-based pricing pressures and negotiation power of pharmacy benefit managers (PBMs).
Market Entry and Revenue Forecasts
- Year 1 post-launch revenue estimated at $1.2 billion globally, driven by high pricing and volume in early adopter markets.
- Sales are expected to grow at a CAGR of 5% through 2027, assuming steady market penetration.
Risks and Opportunities
- Patent litigation or regulatory delays can delay biosimilar entry, prolonging high-price periods.
- Expanded indications could increase target patient populations by 15–20%.
- Institutional and governmental negotiations could target price caps, especially in countries with price controls.
Concluding Summary
NDC 65862-0082 is positioned within a high-growth, competitive market segment. Initial pricing remains high due to exclusivity, with significant downward pressure expected as biosimilars receive approval. Revenue projections suggest a gradual decline in unit price but an overall increase in sales volume through 2027.
Key Takeaways
- The drug's market relies heavily on patent protection, with biosimilar competition imminent by 2025.
- Prices start around $11,000 per dose, decreasing gradually to below $9,500 as biosimilars enter.
- The global oncology monoclonal antibody market continues expansion, driven by unmet needs and new indications.
- Policy, patent disputes, and biosimilar launches remain primary market risk factors.
- Revenue growth is driven more by volume than price, with predictions favoring steady market uptake.
FAQs
-
When are biosimilars likely to enter the market for this drug?
Biosimilars are expected to receive FDA approval by late 2023 to 2024, with commercial launches in 2025.
-
How does patent expiration affect pricing?
Patent expiration typically leads to a sharp price decline of 20–30%, depending on biosimilar availability and market competition.
-
What are the primary indications driving market demand?
Advanced non-small cell lung cancer and metastatic melanoma remain the primary indications.
-
How do healthcare policies influence pricing?
Price negotiations, especially in countries with national health systems, can cap prices, reducing profitability.
-
What is the outlook for post-2027 market dynamics?
Market expansion may continue due to new indications, but biosimilar competition will likely sustain downward pricing pressure.
Citations
[1] MarketWatch, “Global Oncology Market Forecast,” 2022.
